This precision-driven genome editing tool uses chimeric oligonucleotide-directed editing (CODE) to replace, insert, or delete specific genes with exceptional accuracy. The genome editing market, valued at nearly $10 billion in 2024 and anticipated to grow to $25 billion by 2030, faces significant hurdles. Traditional prime editing, while powerful, faces challenges such as varied efficiency across genomic loci, competition between edited and unedited DNA flaps, and inaccuracies like reverse transcriptase overextension.
University of Florida researchers have engineered nCas9 DNA polymerase fusion proteins for CODE systems, which improve efficiency and precision of genome editing by integrating a DNA-dependent DNA polymerase with a chimeric pegRNA. The approach addresses key limitations with traditional prime editing. This genome editing tool is promising for therapeutic applications, offering versatility for precise genome modifications without the need for double-stranded breaks.
Genome editing tool for precise, efficient genome manipulation for gene therapy, research tools, drug discovery and development, and more
This cutting-edge genome editing tool consists of unique chimeric guides and nickase enzymes that precisely target and replace desired sections of DNA. The system's robust capabilities, stemming from the combination of DNA polymerases and engineered proteins, reduce auto-inhibition and leverage the unique properties of DNA polymerases, such as high processivity and proofreading capabilities, to enhance editing efficiency and accuracy. The development of CODEMax and CODEMax(exo+) systems, engineered with a robust Bst DNA polymerase derivative, further improves gene correction efficiency. These systems perform small insertions, deletions, and substitutions more effectively than traditional prime editors, expanding the toolbox for genome manipulation without double-stranded breaks.